Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)

Technology appraisal
Reference number: TA452
Published: 05 July 2017

History

Draft scope documents

Draft scope (pre-referral) (PDF 112 KB)

Published:

01 July 2016
Provisional matrix (pre-referral) (PDF 100 KB)

Published:

01 July 2016

Invitation to participate

Final scope (PDF 82 KB)

Published:

05 July 2016
Final matrix (PDF 90 KB)

Published:

05 July 2016
Draft scope and provisional matrix comments table (post-referral) (PDF 82 KB)

Published:

05 July 2016